Does your CRO Partner with a Specialty Pharmacy?

Does Your CRO Partner With a Specialty Pharmacy?

March 6, 2018

ARG Partnership

Addresses one of the biggest challenges in clinical trials: retention
Provides real-time experience with patients and products
Facilitates faster clinical development from trial to market

ARG is always exploring avenues to further leverage our unique relationships to provide additional value to our sponsors. This includes a one-of-a-kind partnership with a national specialty pharmacy that is aligned with ARG’s plasma-derived therapeutic focus.

The value-add is truly distinctive because specialty pharmacy nursing staff are able to be deployed in the home setting in the investigational phases of development. During rare disease, oncology, and immunology trials, home health clinical staff provided by the specialty pharmacy are able to deliver products directly to the homes of patients.

This is meaningful for patients who would much rather maintain infusion schedules at home. This leads to better compliance in clinical trials and because these visits are often covered by insurance, patients get the benefit of home comfort without additional study costs. In an industry that is plagued with 30% atrophy rates in studies, ARG uses its connections to boost and maintain retention rates.

While delivering the investigational drugs, home health nurses are able to assess protocols, patients, and adverse events, as well as gain experience in processing and shipping the products. Using the data captured and the input from the nurses, companies will be able to build the next generation of safer and better products.

This experience in the clinical setting pays dividends later when the compound is ready for market authorization and during the drive to distribution. It is invaluable to use the same nurses in the investigational and commercial phases of a drug’s development. ARG and our specialty pharmacy partners are able to strategically “overlay” clinical staff into trials to prepare them for the future.

ARG is way ahead of other CROs because our partnership with a specialty pharmacy provides multiple tangible benefits to sponsors.

(Photo by Jenn Evelyn Ann)

Previous Next

Does Your CRO Understand the Ultimate Trial Goal?

ARG's primary goal is to improve and prolong the lives of the people affected by rare diseases through the clinical trials we manage. We realize our patient-centric approach by carefully cultivating relationships, fostering meaningful communication, and anticipating and addressing all of the challenges in our studies.

May 23, 2019

Does Your CRO Innovate To Keep Trials On Track?

ARG knows from experience that the willingness to be flexible has fueled our success in rare disease clinical trials, resulting in approvals with over $3B in sales.

May 9, 2018

Does Your CRO Value Every Single Patient?

Every patient counts. While large-scale intricately-designed studies can afford to lose patients, clinical trials for rare patient populations are not buffered for atrophy. ARG emphasizes that every patient is vital; in fact, we place the utmost importance on every data point in every study.

May 20, 2021